P53 Antagonist Shows Early Activity in Advanced Liposarcoma
CHICAGO — Almost 90% of patients with metastatic liposarcoma achieved disease control with an investigational drug targeting p53 suppression, according to an early study reported at the American Society of Clinical Oncology (ASCO) annual meeting. The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had stable disease and four other […]
Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer
CHICAGO — Patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (Enhertu) achieved significant improvements in survival compared with those treated with chemotherapy alone, according to results from the DESTINY-Breast04 Trial. In the phase III international study, among a population of 494 patients with both HR-positive disease (88.7%) and HR-negative disease (11.3%), the risk […]
End of the Line for a Failed Prostate Cancer Drug
The androgen synthesis inhibitor orteronel failed to improve survival in metastatic hormone-sensitive prostate cancer (mHSPC) despite a twofold improvement in progression-free survival (PFS) versus standard androgen-deprivation therapy (ADT), a large randomized trial showed. Patients randomized to ADT plus orteronel had a median overall survival (OS) of 81 months compared with 70.2 months with ADT plus […]
Consolidation Intensification Fails in High-Risk Metastatic Ewing Sarcoma
Adding high-dose treosulfan and melphalan as further consolidation therapy for high-risk metastatic Ewing sarcoma failed to improve survival outcomes, a randomized phase III study showed. In an intention-to-treat population of 109 patients receiving standard induction and consolidation therapy, no significant difference was seen in event-free survival (EFS) between a group that also received high-dose treosulfan-melphalan […]
FDA Approves First Targeted Radioligand Therapy for Metastatic Prostate Cancer
On Wednesday, the FDA approved the first targeted therapeutic radioligand for progressive, metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen (PSMA) expression. Consisting of a targeting compound and a therapeutic radioisotope, lutetium Lu 177 vipivotide tetraxetan (Pluvicto) hones in on PSMA-expressing mCRPC, as identified by a companion diagnostic test (gallium Ga 68 Gozetotide injection, […]
Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer
In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo […]
Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]
Improved Survival With Surgery in Metastatic Breast Cancer
Selected patients with metastatic breast cancer at diagnosis had significantly better survival with surgery in addition to systemic therapy, an analysis of almost 13,000 patients showed. Overall, the survival hazard improved by 27%-36% in women with known receptor status (estrogen, progesterone, and HER2) treated with systemic therapy plus surgery with or without radiation therapy. Women […]
Molecular Changes Could Guide Metastatic Breast Cancer Therapy
Certain molecular changes in breast cancer genes occurred more often in metastatic disease, possibly suggesting new strategies for difficult-to-treat disease, according to initial data from an ongoing study. Matched tissue specimens from primary tumors and metastases showed higher rates of mutations in driver genes and variations in gene copy number in metastatic breast cancer (MBC). […]